Harkness Pharmaceuticals is currently undertaking a detailed clinical investigation of the effects of oral dosing of enterostatin. The trial is a placebo-controlled, dose-escalation study in healthy obese adults and is due to be completed in 2006.

The trial is designed to achieve several detailed objectives:

• To determine the pharmacokinetics of enterostatin following oral administration;
• To evaluate the safety and tolerability of several dose levels of enterostatin as compared to a placebo in healthy obese adults; and
• To evaluate hunger/satiety ratings following the administration.